<DOC>
	<DOCNO>NCT00101842</DOCNO>
	<brief_summary>The purpose study : To determine maximum tolerate dose Gemcitabine Platinol follow Pemetrexed Gemcitabine patient advance metastatic transitional cell carcinoma urothelium ; To determine safety Gemcitabine Platinol follow Pemetrexed Gemcitabine side effect might associate combination drug ; To determine whether Gemcitabine Platinol follow Pemetrexed Gemcitabine help patient advanced bladder cancer live longer ; To determine whether Gemcitabine Platinol follow Pemetrexed Gemcitabine make tumor small disappear , long .</brief_summary>
	<brief_title>Gemcitabine Platinol Followed Pemetrexed Gemcitabine Patients With Advanced Metastatic Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Biopsyproven metastatic bladder cancer No prior chemotherapy metastatic disease except surgery , complete 6 month enrollment Prior radiation allow , site measurable disease complete 3 week enrollment 18 year age old Pure adeno squamous urothelial cancer Brain metastases cause symptom Have receive treatment within last 30 day drug receive regulatory approval indication Inability take dexamethasone , folic acid vitamin B12 , accord protocol Clinically relevant fluid collection lung abdomen control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>